Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow these two medicines differ, and why that matters for your decision
What the licences actually say, and why it shapes your options
Exenatide (brand names Byetta and Bydureon) is a GLP-1 receptor agonist licensed in the UK exclusively for type 2 diabetes. It is not approved by the MHRA for weight management, and no prescriber can legally issue it for that purpose. If you have seen it discussed in weight-loss forums or older clinical literature, that reflects its off-label history and its role in early GLP-1 research, not its current UK licence. The NHS medicines page for tirzepatide explains tirzepatide's approved uses clearly, and the contrast with exenatide is stark.
Tirzepatide operates on two receptor pathways simultaneously (GIP and GLP-1) making it the only dual-agonist weight-loss medicine licensed in the UK. That dual action produces appetite reduction and slowed gastric emptying through complementary mechanisms. The licence covers adults with a qualifying BMI as part of a programme that includes reduced-calorie eating and increased physical activity. A prescriber, not the medicine itself, determines whether you meet the criteria.
The practical consequence: if weight management is your goal, exenatide is not a legal or clinically appropriate route in the UK. Tirzepatide is. That asymmetry makes this less a head-to-head competition and more a clarification of which medicine actually applies to your situation, and if the relationship between the drug and its brand name is part of what you are untangling, our tirzepatide vs Manjaro explainer sets out how the two terms relate to each other.
What the evidence shows about tirzepatide's weight-loss results
Because exenatide carries no weight-management licence, the clinical trial record for weight loss belongs entirely to tirzepatide. In SURMOUNT-1 (a 72-week trial involving 2,539 adults with obesity) participants taking the 15mg maintenance dose achieved an average body-weight reduction of around 20 to 21%, with some analyses reaching approximately 22.5%. NICE reviewed this evidence as part of Technology Appraisal TA1026, published in December 2024, and recommended tirzepatide for NHS use under specific eligibility criteria.
Exenatide does produce some weight reduction as a secondary effect in people with type 2 diabetes, but trials were not designed with weight loss as the primary endpoint, and the results are not comparable to those from dedicated obesity trials. Citing exenatide figures alongside SURMOUNT-1 data would not be a fair or meaningful comparison.
For readers curious how tirzepatide's results compare with semaglutide or with medicines still in development, the GLP-1 vs tirzepatide comparison covers the class-level picture, and the retatrutide vs tirzepatide page looks at what the pipeline holds. Those are the comparisons where the trial datasets genuinely overlap.
Side-effect profiles: shared roots, different contexts
Both medicines produce gastrointestinal effects (nausea, loose stools, constipation, indigestion) because both act on GLP-1 receptors that slow gastric emptying. With tirzepatide, these effects are most noticeable in the early weeks of treatment or after a dose increase, and they tend to settle as the body adjusts. The treatment overview outlines what patients typically experience.
The important difference is context. When exenatide causes these effects in a person managing type 2 diabetes, they are happening under a diabetes specialist or GP's oversight, with blood glucose monitoring in the picture. When tirzepatide is prescribed for weight management, the clinical framework is different, and at nume, each dose change is reviewed by a prescriber before it proceeds, rather than following an automatic schedule.
The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known but infrequent serious risk with GLP-1 medicines. Severe or persistent stomach pain that spreads to the back warrants urgent medical attention. Patients on either medicine should be aware of this sign. Suspected side effects from any medicine can be reported at the MHRA's Yellow Card scheme.
The comparison in brief
| Factor | Exenatide (Byetta / Bydureon) | Tirzepatide (Mounjaro) |
|---|---|---|
| UK weight-loss licence | No (licensed for type 2 diabetes only | Yes) adults with BMI ≥30, or ≥27 with a weight-related condition |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Average weight reduction (dedicated obesity trial) | Not applicable (no licensed obesity trial | ~20–21% at 15mg over 72 weeks (SURMOUNT-1, NEJM) |
| NICE appraisal for weight management | None | Recommended) TA1026, December 2024 |
| Administration | Twice-daily or once-weekly injection (depending on formulation) | Once-weekly injection via pre-filled KwikPen |
Sources: NICE TA1026; SURMOUNT-1, New England Journal of Medicine; NHS medicines information.
If you are considering tirzepatide for weight management and want to understand how private treatment works, the Mounjaro price comparison page covers what to look for in a provider. For a broader look at where tirzepatide sits relative to other medicines in its class, the tirzepatide vs Mounjaro explainer addresses a common point of confusion about the brand name itself.
Which of these medicines (or any other) is appropriate for you is a clinical decision. Our prescribers review every application individually. Speak to our prescribers by starting your free consultation, and you'll receive a same-day response from a named GPhC-registered clinician. If approved, your Mounjaro KwikPen is dispatched the same day; DPD delivers it the next working day in a plain, unbranded box with tracking sent straight to your phone.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.